Island Pharmaceuticals received approval to commence dosing the third cohort in its single ascending dose study for ISLA-101, a drug candidate repurposed for the prevention and treatment of dengue fever and other mosquito-borne diseases.
The safety review committee, after reviewing the results from the second cohort, confirmed the safety and tolerability of the dosage, enabling Island to proceed with the third cohort.
Island Pharmaceuticals confirmed plans to begin screening and dosing for the third cohort in January 2024.
The results are expected to help optimize protocols for Island’s planned Phase 2a PEACH clinical trial.